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ABSTRACT
Purpose There is ongoing concern regarding increased tox-
icity from paclitaxel in elderly patients, particularly of severe
neutropenia. Yet, data so far is controversial and this concern
is not supported by a clinically relevant age-dependent differ-
ence in pharmacokinetics (PK) of paclitaxel. This study
assessed whether age is associated with increased risk for
paclitaxel-induced neutropenia.
Methods Paclitaxel plasma concentration-time data, pooled
from multiple different studies, was combined with available
respective neutrophil count data during the first treatment
cycle. Paclitaxel pharmacokinetic-pharmacodynamic (PK-
PD) data was modeled using a non-linear mixed effects ap-
proach and a semiphysiological neutropenia model, where
systemic paclitaxel exposure was linked to reduced prolifera-
tion of neutrophils. The impact of age was evaluated on rele-
vant variables in the model, using a significance threshold of
p< 0.005.
Results Paclitaxel PK-PD data was evaluated from 300 pa-
tients, with a median age of 65 years (range 23–84 years),
containing 116 patients ≥70 years (39%). First cycle neutro-
phil counts were adequately described by a threshold effect
model of paclitaxel on the proliferation rate of neutrophils.
Age as a continuous or dichotomous variable (≥70 versus
<70 years) did not significantly impact sensitivity of the bone
marrow to paclitaxel nor the average maturation time of neu-
trophils (both p> 0.005), causing a decline in the respective
interindividual variability of <1%.
Conclusion Results from this large retrospective patient co-
hort do not suggest elderly patients to be at an increased risk of
developing paclitaxel-associated neutropenia during the first
treatment cycle. Reflexive dose reductions of paclitaxel in el-
derly patients are unlikely to improve the risk of severe neu-
tropenia and may be deleterious.
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ABBREVIATIONS
ANCbase Baseline absolute neutrophil count
ANCt Absolute neutrophil count at time t
Cdrug Systemic drug concentration
EC50 Drug concentration at half the maximum
inhibitory effect
Edrug Drug effect
Emax Maximum inhibiting drug effect
Erasmus
MC
Erasmus Medical Center Cancer Institute
FB Feedback
IIV Interindividual variability
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kprol Rate constant for the proliferation of neutrophils
ktr Rate constant for the maturation of neutrophils
MTT Mean transit time
NKI Netherlands Cancer Institute
PK-PD Pharmacokinetic-pharmacodynamic
Radboud
UMC
Radboud University Medical Center
SLOPE Slope factor of linear drug effect
Tc> 0.05μM Time-above-threshold concentration of
0.05 μmol/L
INTRODUCTION
Chemotherapy remains the cornerstone of anticancer treat-
ment and is frequently administered to the ever-growing el-
derly patient population. Dose finding of chemotherapy, in-
cluding paclitaxel, has been based on identifying the maxi-
mum tolerated dose in a small cohort of patients to ultimately
maximize its therapeutic effect in the intended patient popu-
lation. The dose limiting toxicity of paclitaxel is neutropenia,
which may lead to potentially fatal infections (1). Substantial
heterogeneity in treatment-related toxicity has been reported,
and limited available data suggested that elderly patients may
be at an increased risk of paclitaxel-induced neutropenia
(1–3), although data is controversial (1,2,4–7). Pivotal clinical
trials included a relatively small fraction of elderly patients
(17% aged ≥65 years) and reported an overall higher inci-
dence of severe neutropenia (<0.5*109/L) in elderly patients,
which reached statistical significance in two Phase III trials (1).
It has been postulated that an age-related difference may be
driven by a difference in exposure, a depleted bone marrow
reserve, a higher sensitivity to chemotherapy-related hemato-
logical toxicity, and/or a diminished capacity to regain ho-
meostasis after bone marrow stress (8,9). To pursue optimal
treatment outcome, it is key to timely initiate treatment that is
not too aggressive nor too conservative, as both may lead to a
higher morbidity and mortality. A sound understanding of
crucial factors that influence the pharmacokinetic-
pharmacodynamic (PK-PD) relationship facilitates its optimal
use by helping to identify those patient characteristics that
may predispose patients to neutropenia, including older age.
In previous studies, no clinically relevant impact of older age
on the pharmacokinetics of paclitaxel has been established
(10), whereas the time-above-threshold concentration of
0.05 μmol/L (Tc > 0.05μM) has been shown to be related to
paclitaxel-induced hematological toxicity (11–13).
Hypothetically, elderly patients may be at an increased risk
of neutropenia due to increased bone marrow sensitivity rath-
er than increased exposure to paclitaxel. We designed this
study to elucidate the impact of older age on paclitaxel-
i n du c e d n eu t r o p en i a u s i n g a c omp r e h en s i v e
pharmacokinetic-pharmacodynamic model that includes
bone marrow function.
METHODS
Data Collection
Patients who were enrolled in multiple different previously
reported studies were eligible for inclusion in the current da-
tabase. Four of these studies were clinical trials (14–16) and
one study concerned a prospective observational study in
which patients aged 70 years or older were included (10). All
patients were treated with intravenous paclitaxel at the
Netherlands Cancer Institute (NKI; Amsterdam, the
Netherlands), the Erasmus Medical Center Cancer Institute
(Erasmus MC; Rotterdam, the Netherlands), and the
Radboud University Medical Center (Radboud UMC;
Ni jmegen , the Nether lands ) . Pac l i taxe l p la sma
concentration-time data was available from all patients in this
pooled cohort. A median number of 4 PK samples per patient
was drawn in this cohort, ranging from 1 to 20 samples per
patient (10). A more detailed description of study and patient
characteristics have been reported previously (10,14–18). In
the current analysis, patients were excluded from the database
if no neutrophil counts or only baseline neutrophil counts
were available, or if accurate paclitaxel dosing information,
especially concerning dates of paclitaxel treatment, could not
be obtained. Patient characteristics, underlying malignancy,
and baseline laboratory values were available in the pooled
dataset. The first administered paclitaxel dose and associated
neutrophil counts per patient were extracted from electronic
records. If the patient received combination chemotherapy,
dosing information of concomitantly administered chemo-
therapy was added to the database. Neutrophil counts were
determined at multiple time points during paclitaxel treat-
ment, according to routine clinical care as defined by the
clinical treatment protocol or study protocol. All paclitaxel
containing regimes were administered according to standard
procedures of the participating study centers, using standard
premedication, fixed infusion times, and dose reduction
guidelines. In this analysis, only neutrophil counts after the
first treatment cycle were used. All studies were approved by
the institutional ethics committees and were carried out in
acco rdance w i th In t e rna t iona l Con f e r ence on
Harmonisation (ICH) Guidelines for Good Clinical Practice
(19).
Population Pharmacokinetic Model
Individual PK parameters were estimated using a previously
developed 3-compartment model with saturable distribution
and elimination (14). The individual subject PK parameters
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that were estimated in our previously published PK study
were used as PK input in the current study (10). For most
patients, paclitaxel PK sampling was performed during the
first cycle, which coincides with the neutropenia data used
for the modeling. However, for a subset of patients (within a
prospective NKI study and a retrospective Erasmus MC
study) sampling was performed in one of the later treatment
cycles. In the current analysis, the PK parameters for this
subsequent cycle were estimated and used as input for the
neutropenia model for the first cycle.
Semiphysiological Neutropenia Model
A semiphysiological neutropenia model, including continuous
neutrophil count data, was used which links the proliferating
pool of neutrophils to the pool of circulating neutrophils using
three transit compartments that mimick the time delay related
to maturation of neutrophils (20). A first-order rate constant
was estimated for the proliferation (kprol) and maturation (ktr)
of neutrophils. This semiphysiological model, based on
Friberg et al. (20), included a feedback loop, which represented
the homeostatic response to the paclitaxel-induced reduction
in circulating neutrophils. The feedback parameter describing
the neutrophil count recovery after paclitaxel administration
was described by the exponent of the feedback constant (γ) of
the baseline absolute neutrophil count (ANCbase) divided by
the absolute neutrophil count at time t (ANCt), according to
(ANCbase/ANCt)
γ. A chain of three transit compartments was
used (21), thus including four transitions from proliferation to
circulation of neutrophils. The mean transit time (MTT) rep-
resented the average maturation time from the proliferating
stage to circulating neutrophils. The process of proliferation
and maturation of neutrophils was described by the following
equations:
ktr ¼ 4MTT ð1Þ
kprol ¼ ktr*FBð Þ− ktr*Edrug
  ð2Þ
where ktr represents the maturation rate of neutrophils, MTT
represents the mean transit time, kprol represents the prolifera-
tion rate of neutrophils, FB represents feedback, being
(ANCbase/ANCt)
γ and Edrug representing the drug effect of pac-
litaxel. To evaluate the impact of paclitaxel exposure on neu-
trophil counts a linear drug effect (A) as well as a nonlinear
drug effect (B) on kprol was considered, as formulated by the
following equations:
Edrug A ¼ SLOPE*Cdrug ð3Þ
Edrug B ¼ Emax*Cdrug
 
= EC50 þ Cdrug
  ð4Þ
with Edrug representing the drug effect, Cdrug representing the
systemic paclitaxel concentration, Emax representing the
maximum inhibitory effect, which was fixed to 1, and EC50
being the paclitaxel concentration at half the maximum inhib-
itory effect.
Additionally, we evaluated a threshold model in which only
a relevant effect of paclitaxel on kprol was assumed above a
previously established threshold. Moreover, if the paclitaxel
concentration was above this threshold, maximum effect was
assumed (11–13,22–25). This was implemented as follows:
Edrug C ¼ Emax*CdrugHill
 
= EC50
Hill þ CdrugHill
  ð5Þ
with Hill representing the gamma coefficient, which was fixed
at 20 to create an extremely steep concentration-effect model
with EC50 fixed on a predefined threshold total paclitaxel
concentration of 0.05 μmol/L (11–13,22–25).
The drug effect from either one of the above-described eqs.
3–5 was inserted into eq. 2. It was assumed that kprol equals ktr
and that the transition rate was equal for transition through all
three transit compartments, including transit to the central
circulation compartment. Hereto, the following parameters
were estimated: MTT, γ, and either SLOPE, EC50, or Emax
for eq. 3–5, respectively, as presented in Fig. 1.
As a relevant part of the patients received carboplatin in-
fusions concomitantly, the effect of carboplatin on neutrophil
counts was included. Since only carboplatin dosing informa-
tion was available and PK data was lacking, typical PK-PD
parameters of carboplatin were used from a previously pub-
lished analysis by Joerger et al. (26). Hence, an additional lin-
ear drug effect using a slope factor for carboplatin was includ-
ed, as presented in the above-described eq. 3. The following
fixed parameter estimates were used; carboplatin clearance of
7.38 L/h, volume of the central compartment of 11.9 L, vol-
ume of second peripheral compartment of 8.23 L,
intercompartmental clearance between central and second
peripheral compartment of 5.43 L/h, and slope of 1.62 *
10−3 μmol/L (26). Because no other concomitant chemother-
apy was used in the current study cohort, the additive effect of
other cytostatic drugs was not considered.
In the neutropenia model, interindividual variability (IIV)
was estimated onMTT and either on SLOPE, EC50, or Emax,
respectively for assessment of the models described by eqs. 3 to
5 above. The residual error model was characterized using a
proportional error model. Baseline neutrophil counts were
estimated using the observed baseline observations as well as
the residual variability (method B2 according to Dansirikul
et al.) (27).
Model Evaluation of Older Age
The impact of older age was evaluated both as a continuous
variable and as a dichotomous variable (≥70 years versus
<70 years). The effect of this covariate was evaluated on two
PD parameters, namely either SLOPE, EC50, or Emax,
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depending on the chosen final neutropenia model, and on
MTT. For assessment of age as a continuous variable the
following equation was applied:
PDPAR ¼ Θ1* AGEAGEmedian
 θ2
ð6Þ
where PDPAR represents the concerned PD parameter, e.g.
Emax, Θ1 represents the typical population value for the PD
parameter, AGE represents the continuous covariate age, cen-
tered to the median value, Θ2 represents the effect of age.
Assessment of the impact of age as a dichotomous variable
was performed using the following equation:
PDPAR ¼ Θ1*Θ2AGED ð7Þ
where PDPAR again represents the concerned PD param-
eter, Θ1 represents the typical PDPAR value for patients
aged <70 years, Θ2 represents the parameter estimate for
the covariate effect, denoting the proportional increase or
decrease for patients aged ≥70 years, with AGED set 0 for
younger and 1 for elderly patients. Furthermore, the im-
pact of gender and performance status (PS) was also eval-
uated using eq. 7, with PS dichotomized into two groups,
namely PS 0–1 and PS 2–3.
Model evaluation was performed by evaluating successful
and plausible parameter estimation, model stability,
goodness-of-fit (GOF) plots, Visual Predictive Check (VPC)
evaluation with n= 1000, changes in IIV, parameter preci-
sion, and drop in Objective Function Value (OFV) with a
significance threshold of p< 0.005 (dOFV >7.9 for 1 degree
of freedom) for hierarchical models. Precision of parameter
estimates was assessed using sampling importance resampling
(SIR) (28). The relationship between Tc> 0.05μM and estimated
paclitaxel-induced neutropenia was visualized with the final
model parameters, including age both as a continuous vari-
able and dichotomized into two age groups. Hereto, Bayesian
estimates of Tc> 0.05μM, obtained with the POSTHOC option
in NONMEM, were used. Change from baseline neutrophil
to nadir count was calculated also using the Bayesian estimates
of nadir neutrophil count.
Software
Data handling, descriptive data analysis, and data plotting was
performed using R (version 3.0.1). For descriptive analysis, the
Wilcoxon rank sum test and Fisher’s exact test were used, with
the significance threshold set at p< 0.05. Non-linear mixed
effects modeling was executed by NONMEM® (version
7.3.0, ICON Development Solutions, Ellicott City, MD,
USA) and Perl-speaks-NONMEM (version 4.4.8). The first
order conditional estimation with interaction was used as es-
timation method, with Pirana (version 2.9.2) used as a model
interface.
Fig. 1 Schematic presentation of the semiphysiological neutropenia model. Pharmacokinetic model: K21= rate constant of the distribution from the first
peripheral compartment to the central compartment, KMel = plasma concentration at half VMel, KMtr = plasma concentration at half VMtr, Q =
intercompartmental clearance between the central and second peripheral compartment, VMel =maximal elimination rate, VMtr=maximal transport rate from
the central to the first peripheral compartment. Pharmacodynamic model: ANCbase= baseline absolute neutrophil count, ANCt= absolute neutrophil count at
time t, γ=exponent of the feedback constant, Edrug = drug effect, FB= feedback, kprol = rate constant for the proliferation of neutrophils, ktr = rate constant
for the maturation of neutrophils, MTT=mean transit time.
  163 Page 4 of 11 Pharm Res          (2019) 36:163 
RESULTS
Paclitaxel plasma concentration-neutrophil count data of 300
patients was included, with a total of 825 neutrophil count
measurements, of which 300 were baseline measurements,
as presented in Table I. Overall, a median number of 2 neu-
trophil count measurements per patient was available, ranging
from one to eight neutrophil count measurements per patient,
with no measurements below the limit of quantitation.
Median age of the total cohort of patients was 65 years, rang-
ing from 23 to 84 years, and 116 patients were aged ≥70 years
(39%). Our cohort comprised 221 patients who were enrolled
in previous clinical trials, and 79 patients aged 70 years or
older who were included in a previously reported prospective
observational study in daily clinical practice (10). Themajority
of patients received paclitaxel in combination with carboplatin
(88%). Most frequently recorded malignancies were upper
gastro-intestinal and gynaecological cancers. Relatively more
elderly patients were male and received paclitaxel in a weekly
monotherapy regimen compared to their younger counter-
parts receiving 3-weekly treatment, as depicted in Table I.
Remarkably, elderly patients had a significantly higher base-
line neutrophil count compared to their younger counterparts
(p < 0.001, median 5.8 versus 4.4 *109/L, respectively), as
depicted in Table I. Baseline neutrophil counts were available
for all patients included in the current analysis.
Paclitaxel-Induced Neutropenia
During the first treatment cycle, significantly fewer neutrophil
counts were measured in elderly compared to younger pa-
tients (p < 0.001), which was especially evident in the 3-
weekly cohort. Conforming to local treatment protocols nadir
values were generally missing in the prospectively included
cohort of elderly patients treated with 3-weekly paclitaxel in
routine clinical practice.
The paclitaxel-neutrophil relationship was evaluated using
the aforementioned slope, non-linear Emax type and the
threshold models. All three models were able to fit neutrophil
count data and showed plausible parameter estimates. A large
IIV of >50% was observed in each model for SLOPE (80%),
EC50 (220%), or Emax (67%).While all threemodels estimated
a total number of six parameters, the threshold model had the
lowest OFV, with a drop of 35 and 2 points as compared to
the SLOPE and EC50 model, respectively. Model stability,
goodness-of-fit plots, and parameter precision were superior
for the threshold model. Therefore, the threshold model with
a predefined threshold concentration was considered more
appropriate to describe paclitaxel plasma concentration-
neutrophil-time data. Figure 2 shows the observed neutrophil
counts versus population predicted and individual predicted
neutrophil counts by this threshold model. In Fig. 3 the
VPC evaluation with n = 1000 is presented. Parameter
uncertainty distribution was evaluated using SIR, which
showed that estimates had sufficient precision, with the 95%
confidence intervals (CI) depicted in Table II.
In the selected threshold model, the impact of age on
paclitaxel-induced neutropenia was evaluated. Age treated
as a continuous variable did not significantly influence Emax
or MTT (both p> 0.005). The relative standard error (RSE)
of the effect of age on Emax was 68%, whereas the RSE of the
effect of age onMTTwas 53%. The reduction in IIV of either
Emax or MTT was <1%, with a shrinkage of 30% and 32%,
respectively. Evaluation of age handled as dichotomized var-
iable showed similar results on Emax orMTT (both p > 0.005).
In Fig. 4, Tc > 0.05μM was shown against the estimated relative
neutropenia during the first treatment cycle, with age depicted
continuously and dichotomized into two age groups (≥70 versus
<70 years). This graph clearly showed the relation between
Tc> 0.05μM and paclitaxel-induced neutropenia. Introduction
of the covariates gender and PS had no significant effect on
neutropenia.
DISCUSSION
In this comprehensive study cohort, including a substantial
fraction of elderly patients, older age was not significantly
related to the risk of developing paclitaxel-induced neutrope-
nia. Gender and PS also did not significantly influence neu-
tropenia in our study analysis.
Given the small therapeutic window of paclitaxel, extensive
interpatient variability in PK-PD, and hazardous toxicity pro-
file, there remains concern on its safety profile in elderly pa-
tients. As acknowledged by the regulatory authorities, severe
neutropenia was more frequently observed in the elderly pa-
tients, but this difference did not reach significance in the
majority of reported pivotal trials (1). Similarly, conflicting
results are published regarding patients treated in daily clinical
practice. One study reported a significantly higher risk of se-
vere neutropenia in elderly patients (2), although the authors
also stated that this was not accompanied by a significant
difference in clinical consequences as hospitalization, fever,
or need for intravenous antibiotics. Other studies observed
no significant impact of older age on paclitaxel-induced tox-
icity (4–7). One of these studies was a relatively large study
(n= 251) and showed no impact of older age, although the
patient cohorts were younger than the current study (median
58 to 60 years) (7). The other studies included a rather small
number of patients. In one of these studies the younger patient
control group was lacking (5), whereas in another study elderly
patients received lower paclitaxel doses than their younger
counterparts (6). Our study cohort included an extensive and
heterogeneous group of both younger and elderly patients.
Elderly patients had a PS ranging from 0 to 3 and they were
enrolled in clinical trials or treated as part of daily clinical
Pharm Res          (2019) 36:163 Page 5 of 11   163 
Table I Baseline Patients’ Characteristics
Parameter Total cohort Aged <70 yrs Aged ≥70 yrs p value
Number of patients, n (%) 300 (100) 184 (100) 116 (100)
Weekly regimen 172 (57) 80 (43) 92 (79)
3-weekly regimen 128 (43) 104 (57) 24 (21)
Age (y), median [range] 65 [23–84] 58 [23–69] 73 [70–84]
Treatment regimen, (n)
Monotherapy 34 2 32
With carboplatin 263 179 84 <0.001
Unknown 3 3 0
Paclitaxel dose (mg/m2), median [range]
Weekly regimen 51 [38–103] 51 [47–103] 51 [38–101] 0.41
3-weekly combination 173 [130–203] 173 [161–203] 173 [130–179] 0.56
No. of post baseline observations (n) 525 385 140
Per patient, median [range] 1 [1–7] 2 [1–7] 1 [1–4] <0.001
Weekly regimen 1 [1–3] 1 [1–2] 1 [1–3] 0.20
3-weekly regimen 3 [1–7] 3 [1–7] 1 [1–4] <0.001
Sampling time of post baseline observations (days), median [range]
All 10 [2–45] 13 [4–41] 7 [2–45] <0.001
Weekly regimen 7 [2–20] 7 [5–14] 7 [2–20] 0.50
3-weekly regimen 14 [4–45] 14 [4–41] 20 [5–45] 0.002
Female
n, (%) 186 (62) 124 (67) 62 (53) 0.02
Indication, n (%)*
Upper GI 134 (45) 76 (41) 58 (50)
Gynaecological 121 (40) 106 (58) 15 (13)
Breast 31 (10) 2 (1) 29 (25)
Urological 10 (3) 0 10 (9)
Other 3 (1) 0 3 (3)
Unknown 1 (0.3) 0 1 (1)
Hospital
NKI 179 97 82
Erasmus MC 117 87 30
Radboud UMC 4 0 4
Baseline laboratory values
Neutrophil counts (*109/L), median [IQR]
All 4.7 [3.6–6.6] 4.4 [3.5–5.9] 5.8 [4.2–7.4] <0.001
Weekly regimen 4.8 [3.9–6.9] 4.4 [3.8–6.1] 5.5 [4.1–7.2] 0.02
3-weekly regimen 4.6 [3.4–6.1] 4.2 [3.2–5.8] 6.5 [5.5–7.7] <0.001
BSA (m2), median [IQR] 1.8 [1.6–2.0] 1.8 [1.6–1.9] 1.8 [1.7–2.0] 0.01
Performance Status, n (%)*
0–1 264 (88) 161 (88) 103 (89) 0.38
2–3 13 (4) 10 (5) 3 (3)
Unknown 23 (8) 13 (7) 10 (9)
*percentages do not add up to 100% due to rounding
BSA= body surface area, Gynaecological = ovarian, endometrium, mullarian, cervix, and vaginal cancer, h = hours, IQR= interquartile range 25th - 75th
percentile, m2= squared meter, mg=milligrams, n = number of patients, Upper GI= esophageal and cardia cancer, Urological = testis, bladder, prostate, and
kidney cancer, y = years
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practice. Whilst considering the statistically significant age-
related difference in PK, which was not considered clinically
relevant (i.e. a 5% decrease in maximal elimination capacity
for a 10-year increment of age for a typical patient) (10,14),
this comprehensive study showed no significant impact of
older age on the risk of incurring paclitaxel-induced
neutropenia.
Tc > 0.05μM has been shown to be related to paclitaxel treat-
ment efficacy, neuropathy, and hematological toxicity
(11–13,15,16,22–25). Previous studies described a linear drug
effect on neutropenia (14,21). In this study, paclitaxel plasma
concentration-neutrophil count data was adequately de-
scribed by a threshold model using this predefined threshold
concentration of 0.05 μmol/L. Our data showed no signifi-
cant impact of older age on either Emax or MTT, suggesting
that elderly patients were not more sensitive to paclitaxel-
induced neutropenia nor that recovery from hematological
stress was delayed in elderly patients. This study only focused
on neutrophil count data because we had no sound informa-
tion on the occurrence of neutropenic fever. Although the
latter may be of special interest for treating physicians, pacli-
taxel treatment adjustments are based on neutrophil count
measurements in order to prevent neutropenic complications.
Previous studies have consistently shown that first-cycle neu-
tropenia is a good predictor of neutropenic complications in
later treatment cycles (14,30–32). In absence of an effect of
older age on first-cycle neutropenia, it is therefore not expect-
ed that there is an age-related difference in clinical conse-
quences during later treatment cycles. However, some pa-
tients may not have a significant reduction of neutrophil
counts during the first cycle, but may develop gradual reduc-
tion in neutrophil counts after multiple treatment cycles. It
cannot be ruled out that a negligible age-related difference
during the first treatment cycle may be pursued by a larger
difference during the last treatment cycles. Nevertheless, in-
clusion of subsequent cycles may also introduce bias, as it may
appear that neutropenia becomes less severe over multiple
cycles due to the drop out of patients who develop severe
neutropenia in earlier treatment cycles. Furthermore, the risk
of developing peripheral neuropathy was not within the scope
of our study. Although this adverse event was not defined as
the major dose-limiting toxicity, it can be a severe and debil-
itating, especially for elderly patients (1). Neurotoxicity ap-
peared to be cumulative over time, but unfortunately this
information could not be retrieved reliably from all records
of patients included in our cohort.
To provide a forward presentation and interpretation of
the influence of older age, age was assessed as a continuous
and as a dichotomized variable using a cut-off value of
70 years. This cut-off value was used because multiple previ-
ous studies showed a drastic increase in the incidence and
severity of chemotherapy-induced hematological toxicity after
the age of 70 (8). The current study aimed to include all avail-
able paclitaxel PK-PD data frommultiple previous studies. As
a consequence some differences between elderly and younger
patients could not be averted. Interestingly, elderly patients in
the study cohort had a significantly higher median baseline
neutrophil count compared their younger counterparts. This
may be due to the inclusion criteria of historic clinical trials in
which these younger patients were originally included. Per
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Fig. 2 Observed absolute neutrophil counts (ANC) versus population predicted and individual predicted ANC.
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protocol, these trial participants generally have received more
myelosuppressive chemotherapy or more lines of systemic
treatment prior to starting paclitaxel. Besides, cigarette-
smoking patients appeared to have a higher baseline neutro-
phil count compared to nonsmokers (29). Contrary to our
findings, baseline neutrophil counts were higher in younger
patients in this previous study and smokers were significantly
younger than nonsmokers. However, adequate information
about prior lines of chemotherapy and smoking status were
not available in the current cohort. Hence, their contribution
to the observed difference in baseline neutrophil counts could
not be assessed in this study. This is a limitation of the current
study, as a potential bias of prior exposure to myelosuppres-
sive chemotherapy cannot be ruled out. The baseline neutro-
phil count of all patients was available and residual variability
was taken into account in this model. However, the potential
effect of covariates on this baseline value was not evaluated
(27). Since elderly patients in this cohort had a higher baseline
value, it is not likely that the conclusions on the probability of
neutropenia would be altered. Nevertheless, it should be not-
ed that median neutrophil counts at baseline were well within
the normal range in both age groups. In line with the study
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Fig. 3 Visual Predictive Check.
Visual Predictive Check with n=
1000 of post baseline neutrophil
counts, with the dots representing
the observed neutrophil counts, the
solid line representing observed
median counts, and dashed lines
representing the observed 5th and
95th percentiles. The blue areas
indicate the 95% confidence
intervals.
Table II PD parameter estimates of the final neutropenia model
Parameter Estimate 95% Confidence interval
(RSE) [shrinkage]
MTT (h) 158 152–166 (2)
Emax (μmol/L) 2.85 2.57–3.31 (6)
Gamma 0.24 0.22–0.25 (4)
Interindividual variability
MTT (%) 18 16–20 (13) (32)
Emax (%) 67 58–77 (14) (30)
Residual error
σprop (%) 45 44–46 (3) (24)
Emax =maximum inhibiting drug effect, h = hour, MTT=mean transit time,
RSE= relative standard error, σprop = proportional residual error
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design of retrospectively included clinical trials that included
many younger patients, the younger patient group contained
more female patients receiving 3-weekly paclitaxel adminis-
trations. Per protocol, nadir counts were closely monitored in
these clinical trial cohorts, whereas neutrophil counts of pa-
tients treated in routine clinical practice were generally only
monitored at each hospital visit. For the weekly regimen, the
planned hospital visit nearly coincided with the nadir value.
Yet, in the 3-weekly cohort, data from patients treated in daily
clinical practice was relatively sparse and nadir counts were
not routinely measured in clinical practice. In the
semiphysiological neutropenia model differences in e.g. pacli-
taxel dose and timing of neutrophil count data were consid-
ered. Model evaluation did not reveal a significant impact of
older age on the risk of developing neutropenia.
For a part of the study cohort PK sampling was not per-
formed during the first treatment cycle but was performed
during one of the later treatment cycles. In this study, the
PK parameters for this subsequent cycle were estimated and
used as input for the neutropenia model for the first treatment
cycle. It should be noted, however, that this approach did not
consider interoccasion variability, which was 16% for the
elimination capacity of paclitaxel in the previous PK study
(10). This patient cohort did not include other paclitaxel-
based formulations, e.g. albumin-bound paclitaxel.
Therefore, the estimates of this PK-PDmodel may not predict
the probability of neutropenia of other paclitaxel formula-
tions. Paclitaxel is rarely administered in monotherapy and
this study included different paclitaxel treatment regimens ad-
ministered either in monotherapy or, for the majority of in-
cluded patients, concomitantly with carboplatin treatment.
Previous studies reported no influence of carboplatin on the
PK of paclitaxel (33,34). Carboplatin may, however, contrib-
ute to the development of neutropenia, although the effect of
carboplatin on neutrophil counts appeared minimal (1.62 *
10−3 μmol/L) (26). Because of mechanistic plausibility, and to
preclude bias, we added a drug effect of carboplatin to the
neutropenia model based on a previously developed linear
drug effect model. Because no PK data of carboplatin was
available, the PK-PD parameters of carboplatin were fixed
(26). Renal clearance was not considered in this previous
study, but given the small effect of carboplatin on neutropenia,
it is not expected that this may thwart our findings. Other
covariates besides age may influence the risk of developing
neutropenia, such as gender and PS. In a previous study,
females were more likely to develop paclitaxel-induced neu-
tropenia (7). However, in the current study gender did not
significantly affect neutropenia, which is in line with the drug
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Fig. 4 Time-above-threshold paclitaxel concentration of 0.05 μmol/L versus estimated neutrophil count decline (% change) depicted by age. With time-above-
threshold concentration of 0.05 μmol/L depicted in hours and estimated neutrophil count decline calculated as the percentage change in neutrophil count from
baseline to nadir per patient. Age was depicted in years, displayed both as a continuous and as a dichotomous variable (≥70 versus <70 years).
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label (1). It should also be kept in mind that gender significant-
ly influenced paclitaxel PK and that this effect was already
incorporated in the current PK-PD analysis (i.e. males had a
12% higher maximal elimination capacity) (10). One may
argue that not older age but PS or a combination of both
may have predictive value for chemotherapy-induced toxicity.
Although PS is commonly used to predict chemotherapy-
induced toxicity in cancer patients, this is not validated in
elderly patients. Hurria et al. determined no association be-
tween PS and treatment toxicity in elderly patients (35). To
preclude bias, we assessed the influence of PS on neutropenia.
Our analysis supported the findings byHurria et al. that PS did
not significantly affect neutropenia. Validated tools, including
var ious quest ionnaires , are avai lable to predict
chemotherapy-induced toxicity in elderly patients (35), but
these are generally not implemented in clinical practice and
were not available for patients included in the current dataset.
In conclusion, the paclitaxel plasma concentration-
neutropenia relationship was adequately described by a
threshold model, using a predefined threshold concentration
of 0.05 μmol/L. Results from this comprehensive retrospec-
tive patient cohort do not suggest elderly patients to be at an
increased risk of paclitaxel-associated neutropenia. A priori
dose reductions of paclitaxel in elderly patients are unlikely
to improve the risk of severe neutropenia and may impair
treatment outcome.
ACKNOWLEDGMENTS AND DISCLOSURES
The authors wish to express their gratitude to all study partic-
ipants and health care employees involved in patient inclu-
sion, with special thanks to Ellen van der Pan and Anoek
van Straten. The authors thank the Research High
Performance Computing facility of the NKI for support in
the use of computational resources. Jos H. Beijnen is a (part-
time) employee and shareholder of Modra Pharmaceuticals,
and (partly) holds a patent on oral taxane pharmaceutical
formulations. The other authors declare no conflicts of interest
in connection with this manuscript. All procedures performed
in studies involving human participants were in accordance
with the ethical standards of the institutional research com-
mittees and was carried out in accordance with ICH
Guidelines for Good Clinical Practice. Written informed con-
sent was obtained from all individual participants.
REFERENCES
1. Food and Drug Administration. TAXOL (paclitaxel), NDA
020262. 2011.
2. Lichtman SM, Hollis D, Miller A A, Rosner GL, Rhoades C A,
Lester EP, et al. Prospective evaluation of the relationship of patient
age and paclitaxel clinical pharmacology: Cancer and leukemia
group B (CALGB 9762). J Clin Oncol 2006;24:1846–1851.
3. Lichtman SM, Hurria A, Cirrincione CT, Seidman AD, Winer E,
Hudis C, et al. Paclitaxel efficacy and toxicity in older women with
metastatic breast cancer: combined analysis of calgb 9342 and
9840. Ann Oncol. 2012;23:632–8.
4. Nakamura Y, Sekine I, Furuse K, Saijo N. Retrospective compar-
ison of toxicity and efficacy in phase II trials of 3-h infusions of
paclitaxel for patients 70 years of age or older and patients under
70 years of age. Cancer Chemother Pharmacol. 2000;46:114–8.
5. Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M,
et al. Measurement and impact of co-morbidity in elderly patients
with advanced non-small cell lung cancer treated with chemother-
apy. A phase II study of weekly paclitaxel. Clin Cancer Res. 2001;7:
3942–9.
6. Smorenburg CH, Ten Tije AJ, Verweij J, Bontenbal M, Mross K,
Van Zomeren DM, et al. Altered clearance of unbound paclitaxel
in elderly patients with metastatic breast cancer. Eur J Cancer.
2003;39:196–202.
7. Nieuweboer AJ, Smid M, de Graan A-JM, Elbouazzaoui S, de
Bruijn P, Martens JW, et al. Predicting paclitaxel-induced neutro-
penia using the DMET platform. Pharmacogenomics. 2015;16:
1231–41.
8. Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact
on cancer management and decision making, part II. Cancer J.
2005;11:461–73.
9. Aapro M, Skacel T, von Minckwitz G, Lawrinson S,
Schwenkglenks M, Lyman GH, et al. Pegfilgrastim primary pro-
phylaxis vs. current practice neutropenia management in elderly
breast cancer patients receiving chemotherapy. Crit Rev Oncol
Hematol. 2009;74:203–10.
10. Crombag M-RB, de Vries SA, Koolen SL, Wijngaard S, Joerger
M, Schellens JH, et al. Impact of older age on the exposure of
paclitaxel: a population pharmacokinetic study. Pharm Res.
2019;36.
11. Gianni BL, Kearns CM, Giani A, Capri G, Vigan L, Locatelli A,
et al. Nonlinear pharmacokinetics andmetabolism of paclitaxel and
its pharmacokinetic/Pharmacodynamic relationships in humans. J
Clin Oncol. 1995;13:180–90.
12. Ohtsu T, Sasaki Y, Tamura T, Nishiwaki Y, Saijo N. Clinical
pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour
infusion versus a 24-hour infusion. Clin Cancer Res. 1995;1:599–
606.
13. Xin D, Zhou L, Li C, Zhang S, Huang H, Qiu G, et al. TC > 0.05
as a pharmacokinetic parameter of paclitaxel for therapeutic effica-
cy and toxicity in Cancer patients. Recent Pat Anticancer Drug
Discov. 2018;13:341–7.
14. Joerger M, Kraff S, Huitema ADR, Feiss G, Moritz B, Schellens
JHM, et al. Evaluation of a pharmacology-driven dosing algorithm
of 3-weekly paclitaxel using therapeutic drug monitoring: A
pharmacokinetic-pharmacodynamic simulation study. Clin
Pharmacokinet. 2012;51:607–17.
15. De Graan AJM, Elens L, Smid M, Martens JW, Sparreboom A,
Nieuweboer AJM, et al. A pharmacogenetic predictive model for
paclitaxel clearance based on the DMET platform. Clin Cancer
Res. 2013;19:5210–7.
16. De Graan AJM, Elens L, Sprowl JA, Sparreboom A, Friberg LE,
Van Der Holt B, et al. CYP3A4*22 genotype and systemic expo-
sure affect paclitaxel-induced neurotoxicity. Clin Cancer Res.
2013;19:3316–24.
17. Joerger M, Huitema ADR, van den Bongard DHJG, Schellens
JHM, Beijnen JH. Quantitative effect of gender, age, liver function,
and body size on the population pharmacokinetics of paclitaxel in
patients with solid tumors. Clin Cancer Res. 2006;12:2150–7.
18. Kraff S, Nieuweboer AJM, Mathijssen RHJ, Baty F, De Graan AJ,
Van Schaik RHN, et al. Pharmacokinetically based dosing of week-
ly paclitaxel to reduce drug-related neurotoxicity based on a single
sample strategy. Cancer Chemother Pharmacol. 2015;75:975–83.
  163 Page 10 of 11 Pharm Res          (2019) 36:163 
19. The International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human
Use. (ICH) 2018. www.ich.org.
20. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO.
Model of chemotherapy-inducedmyelosuppression with parameter
consistency across drugs. J Clin Oncol. 2002;20:4713–21.
21. Henrich A, Joerger M, Kraff S, Jaehde U, Huisinga W, Kloft C,
et al. Semimechanistic bone marrow exhaustion pharmacokinetic/
Pharmacodynamic model for chemotherapy-induced cumulative
neutropenia s. J Pharmacol Exp Ther J Pharmacol Exp Ther.
2017;362:347–58.
22. Mielke S, Sparreboom A, Steinberg SM, GelderblomH, Unger C,
Behringer D, et al. Association of Paclitaxel Pharmacokinetics with
the development of peripheral neuropathy in patients with ad-
vanced Cancer. Clin Cancer Res. 2005;11:4843–50.
23. Mielke S, Mross K, Gerds T A, Schmidt A, Wäsch R, Berger DP,
et al. Comparative neurotoxicity of weekly non-break paclitaxel in-
fusions over 1 versus 3 h. Anti-Cancer Drugs 2003;14:785–792.
24. Joerger M, Von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler
TC. Open-label, randomised study of individualized,
pharmacokinetically (PK)-guided dosing of paclitaxel combined
with carboplatin or cisplatin in patients with advanced non-small
cell lung cancer (NSCLC). Ann Oncol. 2016;27:1895–902.
25. Mielke S, Sparreboom A, Behringer D, Mross K. Paclitaxel phar-
macokinetics and response to chemotherapy in patients with ad-
vanced cancer treated with a weekly regimen. Anticancer Res.
2005;25:4423–7.
26. Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N,
Briasoulis E, et al. Population pharmacokinetics and pharmacody-
namics of paclitaxel and carboplatin in ovarian cancer patients: A
study by the European organization for research and treatment of
cancer-pharmacology and molecular mechanisms group and new
drug development group. Clin Cancer Res. 2007;13:6410–8.
27. Dansirikul C, Silber HE, Karlsson MO. Approaches to handling
pharmacodynamic baseline responses. J Pharmacokinet
Pharmacodyn. 2008;35:269–83. https://doi.org/10.1007/
s10928-008-9088-2.
28. Dosne AG, Bergstrand M, Harling K, Karlsson MO. Improving
the estimation of parameter uncertainty distributions in nonlinear
mixed effects models using sampling importance resampling. J
Pharmacokinet Pharmacodyn. 2016;43:583–96.
29. de Graan A-JM, Loos WJ, Friberg LE, Baker SD, van der Bol JM,
van Doorn L, et al. Influence of smoking on the pharmacokinetics
and toxicity profiles of Taxane therapy. Clin Cancer Res. 2012;18:
4425–32.
30. Fontanella C, Bolzonello S, Lederer B, Aprile G. Management of
breast cancer patients with chemotherapy-induced neutropenia or
febrile neutropenia. Breast Care. 2014;9:239–45.
31. Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R,
Constenla M, et al. Neutropenia occurrence and predictors of re-
duced chemotherapy delivery: results from the INC-EU prospec-
tive observational European neutropenia study. Support Care
Cancer. 2008;16:1299–309.
32. Rivera E, Haim Erder M, Fridman M, Frye D, Hortobagyi GN.
First-cycle absolute neutrophil count can be used to improve
chemotherapy-dose delivery and reduce the risk of febrile neutro-
penia in patients receiving adjuvant therapy: a validation study.
Breast Cancer Res. 2003;5:114–20. https://doi.org/10.1186/
bcr618.
33. Belani BCP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D,
Zacharski D, et al. Phase I Trial , Including Pharmacokinetic and
Pharmacodynamic Correlations, of Combination Paclitaxel and
Carboplatin in Patients With Metastatic Non–Small-Cell Lung
Cancer. J Clin Oncol 1999;17:676–684
34. Huizing MT, van Warmerdam LJ, Rosing H, Schaefers MC, Lai
A, Helmerhorst TJ, et al. Phase I and pharmacologic study of the
combination paclitaxel and carboplatin as first-line chemotherapy
in stage III and IV ovarian cancer. J Clin Oncol. 1997;15:1953–64.
35. Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A,
et al. Validation of a prediction tool for chemotherapy toxicity in
older adults with Cancer. J Clin Oncol. 2016;34:2366–71.
Publisher’s Note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Pharm Res          (2019) 36:163 Page 11 of 11   163 
